GlobeNewswire Inc | Mar 4, 2021 04:05PM EST

March 04, 2021

CHARLOTTESVILLE, Va., March 04, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN)(Diffusion or the Company), an innovative biopharmaceutical company developing novel therapies that enhance the bodys ability to deliver oxygen to areas where it is needed most, announced today that Robert J. Cobuzzi, Ph.D., CEO of Diffusion, willpresent atthe H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021.The presentation will be available on demand during the virtual event for all registered attendees.

Event details are as follows:

Event: H.C. Wainwright Global Life Sciences ConferenceDate: Tuesday, March 9, 2021 to Wednesday, March 10, 2021Time: Available on DemandRegistration: https://hcwevents.com/globalconference/

Duringthepresentation, Dr. Cobuzzi willprovide an overview ofDiffusions recent corporate achievements, planned clinical trials, as well as potential milestones. Our presentation will be availablehere, on the Investor Relations section of our website following the conference.

About Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Inc. is an innovative biopharmaceutical company developing novel therapies that enhance the bodys ability to deliver oxygen to areas where it is needed most. Diffusions lead product candidate, trans sodium crocetinate(TSC), is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicines most intractable and difficult-to-treat conditions. In addition to TSC, Diffusions product candidate DFN-529, a novel, allosteric PI3K/Akt/mTOR Pathway inhibitor, is in early-stage development. For more information, please visit us at www.diffusionpharma.com.

Forward-Looking Statements

This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding the anticipated use of proceeds from the offering. The Company may, in some cases, use terms such as believes, estimates, anticipates, expects, plans, intends, may, could, might, will, should, approximately, or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Although the Company believes that it has a reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Companys control, and as a result the Companys actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risk and uncertainties include, among other things, those related to: the Companys ability to design, initiate, execute, and complete its ongoing and planned studies evaluating TSC;; the Companys ability to develop and commercialize TSC or any other product candidate; general economic, political, business, industry, and market conditions, including the ongoing COVID-19 pandemic; and the other factors discussed under the heading Risk Factors in the Companys filings with the U.S. Securities and Exchange Commission (SEC). Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified) and, except as required by applicable law, rule, or regulation, the Company undertakes no obligation to update any such statements after the date hereof.

ContactsInvestors:Tiberend Strategic Advisors, Inc.Maureen McEnroe, CFA/Miriam Weber Miller(212)375-2664 / (212) 375-2694mmcenroe@tiberend.com/mmiller@tiberend.com

Media:Jeffrey FreedmanRooneyPartners(646) 432-0191jfreedman@rooneyco.com